Newswire (Published: Thursday, January 10, 2019, 10:00:00 AM CST, Received: Thursday, January 10, 2019, 1:18:33 PM CST)

Word Count: 429

By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting originating in Los Angeles, California, by NewsRx journalists, research stated, "To query specialty-specific differences regarding postoperative radiotherapy (RT) for high-risk prostate cancer. Electronic mail survey of radiation oncologists (ROs) and urologists."

The news reporters obtained a quote from the research from the University of California, "We sought to maximize absolute response number to capture contemporary practice ethos. The outcome of interest was association between response and specialty. Training level/expertise, practice setting, percentage of consultation caseload consisting of high-risk prostate cancer, and nationality were set as effect modifiers for multivariate logistic regression. In total, 846 ROs and 407 urologists responded. ROs were more likely to prefer adjuvant radiotherapy (ART). ART or early salvage radiotherapy (SRT, with early SRT defined as that delivered at prostate-specific antigen < 0.2), whereas urologists were more likely to prefer early or delayed SRT (P < 0.0001). ROs were more likely to prefer lower PSA thresholds for initiating SRT (P < 0.0001), and more likely to recommend ART in the setting of adverse pathologic features or node-positive disease (P < 0.0001). Significantly more ROs would recommend concurrent androgen deprivation therapy or pelvic nodal RT in the setting of node-positive or Gleason score 8 to 10 disease (P < 0.0001). Specialty-specific differences were readily elucidated with respect to timing and indications for ART and SRT, as well as for indications for androgen deprivation therapy and nodal RT."

According to the news reporters, the research concluded: "These differences are likely to create a sense of dissonance for patients, which may in turn explain the underutilization of postoperative RT in general practice."

For more information on this research see: Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. American Journal of Clinical Oncology-Cancer Clinical Trials, 2018;41(8):739-746. American Journal of Clinical Oncology-Cancer Clinical Trials can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA (see also Oncology - Prostate Cancer).

Our news correspondents report that additional information may be obtained by contacting A.U. Kishan, University of California, David Geffen Sch Med, Dept. of Radiat Oncol, Los Angeles, CA 90095, United States. Additional authors for this research include G. Duchesne, P.C. Wang, J.C.M. Rwigema, A.U. Kishan, C. Saigal, M. Rettig, M.L. Steinberg and C.R. King.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of California
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

North America
United States
Americas
California
Pennsylvania
Los Angeles
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Radiology
            Urology
      Treatments and Therapies
            Radiation Therapy